Dovey Z, Nair S, Chakravarty D, Tewari A
Cancer Rep (Hoboken). 2021; 4(5):e1340.
PMID: 33599076
PMC: 8551995.
DOI: 10.1002/cnr2.1340.
Al Zoubi M, Otoum R, Alorjani M, Al Bashir S, Al Trad B, Abualrja M
Asian Pac J Cancer Prev. 2020; 21(11):3365-3371.
PMID: 33247697
PMC: 8033120.
DOI: 10.31557/APJCP.2020.21.11.3365.
He Y, Johnson D, Yang J, Wu H, You S, Yoon J
Oncogene. 2019; 38(38):6507-6520.
PMID: 31358900
PMC: 6752978.
DOI: 10.1038/s41388-019-0901-8.
Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J
PLoS One. 2018; 13(10):e0205837.
PMID: 30321230
PMC: 6188866.
DOI: 10.1371/journal.pone.0205837.
Chopra H, Khan Z, Contreras J, Wang H, Sedrak A, Zhu Y
Oncotarget. 2018; 9(5):6270-6281.
PMID: 29464071
PMC: 5814211.
DOI: 10.18632/oncotarget.23569.
Integrated Bioinformatics Analysis of Potential Biomarkers for Prostate Cancer.
Tan J, Jin X, Wang K
Pathol Oncol Res. 2017; 25(2):455-460.
PMID: 29260398
DOI: 10.1007/s12253-017-0346-8.
Genetic alterations in benign prostatic hyperplasia patients.
Mohamed H, Aly M, Hussein T
Ger Med Sci. 2017; 15:Doc16.
PMID: 29234244
PMC: 5705825.
DOI: 10.3205/000257.
Significance of p53 and ki-67 expression in prostate cancer.
Verma R, Gupta V, Singh J, Verma M, Gupta G, Gupta S
Urol Ann. 2015; 7(4):488-93.
PMID: 26692671
PMC: 4660702.
DOI: 10.4103/0974-7796.158507.
Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis.
Zhang X, Wu J
Prostate Int. 2015; 3(3):71-4.
PMID: 26473147
PMC: 4588372.
DOI: 10.1016/j.prnil.2014.09.001.
Nuclear iASPP may facilitate prostate cancer progression.
Morris E, Cerundolo L, Lu M, Verrill C, Fritzsche F, White M
Cell Death Dis. 2014; 5:e1492.
PMID: 25341046
PMC: 4649527.
DOI: 10.1038/cddis.2014.442.
Molecular pathways in prostate cancer.
Mazaris E, Tsiotras A
Nephrourol Mon. 2013; 5(3):792-800.
PMID: 24282788
PMC: 3830904.
DOI: 10.5812/numonthly.9430.
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J, Roh M, Doubinskaia I, Algarroba G, Eltoum I, Abdulkadir S
Oncogene. 2011; 31(3):322-32.
PMID: 21685943
PMC: 3179816.
DOI: 10.1038/onc.2011.236.
Negative regulation of the tumor suppressor p53 gene by microRNAs.
Kumar M, Lu Z, Takwi A, Chen W, Callander N, Ramos K
Oncogene. 2010; 30(7):843-53.
PMID: 20935678
PMC: 3021102.
DOI: 10.1038/onc.2010.457.
Targeting prostate cancer based on signal transduction and cell cycle pathways.
Lee J, Lehmann B, Terrian D, Chappell W, Stivala F, Libra M
Cell Cycle. 2008; 7(12):1745-62.
PMID: 18594202
PMC: 2593475.
DOI: 10.4161/cc.7.12.6166.
Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.
Lehmann B, McCubrey J, Terrian D
Cancer Biol Ther. 2007; 6(8):1165-70.
PMID: 18059157
PMC: 2889025.
DOI: 10.4161/cbt.6.8.4544.
Penile apoptosis in association with p53 under lack of testosterone.
Yamamoto H, Sasaki S, Tatsura H, Umemoto Y, Kubota H, Kamiya H
Urol Res. 2003; 32(1):9-13.
PMID: 14685795
DOI: 10.1007/s00240-003-0358-6.
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.
Isaacs J
Am J Pathol. 1997; 150(5):1511-21.
PMID: 9137077
PMC: 1858207.
Molecular biology of prostate cancer.
Shi X, Gumerlock P, deVere White R
World J Urol. 1996; 14(5):318-28.
PMID: 8912472
DOI: 10.1007/BF00184605.
Prostate cancer progression. Implications of histopathology.
Ware J
Am J Pathol. 1994; 145(5):983-93.
PMID: 7977655
PMC: 1887423.
Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
Mirchandani D, Zheng J, Miller G, Ghosh A, Shibata D, Cote R
Am J Pathol. 1995; 147(1):92-101.
PMID: 7604888
PMC: 1869872.